• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
PER
Click for more information
6.25% 6.8¢

PERCHERON THERAPEUTICS LIMITED

Market Cap $61.30M  ! watchlist Created with Sketch. Add to my watchlist
Healthcare

Percheron Therapeutics Limited, formerly Antisense Therapeutics Limited, is a... Percheron Therapeutics Limited, formerly Antisense Therapeutics Limited, is a biotechnology company. The Company is engaged in developing and commercializing antisense pharmaceuticals for large unmet markets in rare diseases. The Company’s products include ATL1102 for Duchenne muscular dystrophy (DMD), ATL1103 for Acromegaly, and ATL1102 for Multiple Sclerosis (MS). ATL1102, is an antisense inhibitor targeting very late antigen 4 (VLA-4), an immune cell molecule. ATL1103 is a second-generation antisense drug designed to block growth hormone receptor (GHr) expression thereby reducing levels of the hormone insulin-like growth factor-I (IGF-I) in the blood and is a potential treatment for diseases associated with excessive growth hormone action. By inhibiting GHr production, ATL1103 in turn reduces IGF-I levels in the blood (serum). The Company is conducting a Phase II clinical trial of ATL1102 in DMD patients.More

Latest Threads

Tag Subject Date Created with Sketch. Comments Created with Sketch. Views Created with Sketch.
PER
per-chart
9 10 11
20:52 605 134K
20:52 Last post  nayr04 Comments Created with Sketch.  605  Views Created with Sketch.  134K 
PER
Ann: Change in substantial holding 		26/04/24 1 531
26/04/24 Last post  Wise_One Comments Created with Sketch.  1  Views Created with Sketch.  531 
PER
PER - Megathread
3 4 5
26/04/24 250 72K
26/04/24 Last post  Wise_One Comments Created with Sketch.  250  Views Created with Sketch.  72K 
PER
No title but imagination 		17/04/24 3 1.3K
17/04/24 Last post  Bluesky24 Comments Created with Sketch.  3  Views Created with Sketch.  1.3K 
PER
Why Clinicians could switch from Corticosteroids to Atl1102 		11/04/24 0 255
11/04/24 Last post  itsagas Comments Created with Sketch.  0  Views Created with Sketch.  255 
PER
Ann: ATL1102 Clinical Trial Update 		02/04/24 16 5.3K
02/04/24 Last post  itsagas Comments Created with Sketch.  16  Views Created with Sketch.  5.3K 
PER
Ann: Update - Proposed issue of securities - ANP
2 3
26/03/24 156 47K
26/03/24 Last post  mow1 Comments Created with Sketch.  156  Views Created with Sketch.  47K 
PER
Ann: ATL1102 Data presented at MDA Annual Conference 		04/03/24 8 3.8K
04/03/24 Last post  itsagas Comments Created with Sketch.  8  Views Created with Sketch.  3.8K 

See All Discussions arrow Created with Sketch.

Timeline

Change in substantial holding
26 Apr 16:59
 
ATL1102 Clinical Trial Update
02 Apr 09:07
 
ATL1102 Data presented at MDA Annual Conference
04 Mar 08:49
 
Half Yearly Report and Accounts
28 Feb 17:20
 
Percheron Therapeutics Limited Corporate Presentation
26 Feb 08:27
 
Change of Registered Office and Principal Place of Business
21 Feb 08:22
 
View More arrow Created with Sketch.

Featured News

ASM Aust Strategic sees Canada join US in possible funding push for Dubbo
right-arrow Created with Sketch.
CC9 Chariot ends quarter charged up on lithium find in Wyoming
right-arrow Created with Sketch.
NCK Nick Scali moves into the UK market through Fabb Furniture acquisition
right-arrow Created with Sketch.
RDN Raiden's key target areas found drill ready in cultural heritage survey
right-arrow Created with Sketch.
NEWS Recharged Prospects: ‘Watts’ on the horizon for copper & lithium
right-arrow Created with Sketch.
RCE Recce wins safety board approval to dose 4g in R327 UTI infusion trial
right-arrow Created with Sketch.
(20min delay)
Last
6.8¢ 		Change
0.004(6.25%) 		Mkt cap ! $61.30M
Open High Low Value Volume
6.6¢ 7.1¢ 6.5¢ $198.2K 2.885M

Buyers (Bids)

No. Vol. Price($)
1 14845 6.8¢
 

Sellers (Offers)

Price($) Vol. No.
7.2¢ 10000 1
View Market Depth
Last trade - 16.10pm 26/04/2024 (20 minute delay) ?
Last
6.8¢ 		  Change
0.004 ( 14.3 %)
Open High Low Volume
6.6¢ 7.1¢ 6.6¢ 295714
Last updated 15.58pm 26/04/2024 ?
PER (ASX) Chart

Top Stories

Crypto world awaits overnight Bitcoin halving event

The four-yearly Bitcoin halving is set to happen in the early hours of tomorrow morning (Saturday, April 20) - it's an event that industry leader Swyftx likened to 'the Olympic Games for the crypto industry'.
Raiden’s jump into lithium territory in WA’s Pilbara echoes earlier journey by Azure In its bid to define a noteworthy lithium deposit in WA’s Pilbara region, Raiden Resources is following in the footsteps of another explorer.
1970s on repeat, but there's a silver lining! ABBA fans across Australia know that the 1970s were not only about nervous shuffles to the strains of Dancing Queen, across the linoleum floor at the local Blue Light Disco. Oil had only recently begun to rise, and so synthetic fabrics, like polyester, were very popular. So was central heating, using fuel oil. This is all ancient history now and it would not matter except for the fact that history is now rhyming so hard.
Recce Pharmaceuticals up 6% on new antibiotic production milestone Recce Pharmaceuticals (ASX:RCE) is trading up more than 6 per cent after producing a 5000-dose batch of its new antibiotic RECCE 327 (R327) under Good Manufacturing Practises (GMP) standards.
Week 17 Wrap: BHP-Anglo deal helps push down ASX; US data of concern but AI bulls happy The big thematics and headlines that drove the ASX this week, plus, the headlines I think investors ought to be keeping eyes on.

Featured News

CC9 Chariot ends quarter charged up on lithium find in Wyoming
right-arrow Created with Sketch.
BHP BHP confirms £31.1B takeover bid for Anglo American
right-arrow Created with Sketch.
RCE Recce wins safety board approval to dose 4g in R327 UTI infusion trial
right-arrow Created with Sketch.
RDN Raiden's key target areas found drill ready in cultural heritage survey
right-arrow Created with Sketch.
ASM Aust Strategic sees Canada join US in possible funding push for Dubbo
right-arrow Created with Sketch.
NCK Nick Scali moves into the UK market through Fabb Furniture acquisition
right-arrow Created with Sketch.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.